This bill adds FDA‑approved HIV prevention drugs (commonly called PrEP and PEP) and the clinical services that come with them to the list of benefits that must be covered without patient cost‑sharing in federally regulated private plans and several federal programs. It also restricts the use of preauthorization for those services, while tying clinical follow‑up and counseling to current U.S. Public Health Service guidance.
By removing copays, deductibles, coinsurance, and many utilization‑management hurdles, the measure is designed to lower access barriers and increase uptake of biomedical HIV prevention. That improves public‑health reach but reallocates costs to insurers, federal programs, and state Medicaid budgets—and creates operational work for payers and providers to adapt formularies, billing, and clinical workflows.
At a Glance
What It Does
The bill amends the Public Health Service Act and multiple sections of the Social Security Act to require no‑cost coverage of FDA‑approved HIV prevention drugs and related laboratory, counseling, and follow‑up services. It creates a specific prohibition on preauthorization for those services (with a narrow therapeutic‑equivalence exception) and imposes parallel requirements on Medicare Part B and Part D, Medicaid, CHIP, and the Federal Employees Health Benefits Program.
Who It Affects
The rule applies to group and individual market plans subject to PHSA section 2713, Medicare fee‑for‑service and Part D sponsors, state Medicaid and CHIP programs (including benchmark plans), and FEHB carriers. Employers sponsoring self‑insured plans that rely on ERISA exemptions will be affected to the extent federal requirements cascade onto those plans or plan fiduciaries adopt similar coverage.
Why It Matters
This is a cross‑program, statutory approach to eliminating financial and many administrative barriers to biomedical HIV prevention—likely to increase uptake of PrEP/PEP, change utilization patterns, and shift spending from patients to public and private payers. It also constrains a common utilization‑management tool (prior authorization), forcing payers to rely on other controls such as formulary management and therapeutic equivalence.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill changes the baseline benefits and utilization rules that apply across multiple U.S. health programs. For private insurers, it inserts HIV prevention drugs and all clinically recommended services into the preventive‑services list so that eligible plans cannot impose patient cost‑sharing for those items.
At the same time the statute adds a narrowly worded bar on preauthorization: plans may not require prior authorization for the covered HIV prevention services except where a plan requires it for a particular drug but does not require it for a therapeutically equivalent alternative.
For Medicare, the measure creates an explicit ‘‘HIV prevention services’’ benefit definition and then adjusts Part B payment and beneficiary liability rules so that such services are paid at 100 percent of the lesser of actual charge or applicable fee schedule amount (with separate outpatient‑department payment rules preserved). It also carves HIV prevention drugs out of Part D cost‑sharing, adding statutory language that the Part D deductible and cost‑sharing do not apply to covered drugs used for HIV prevention and aligning beneficiary subsidy rules accordingly.On the Medicaid and CHIP side, the bill makes HIV prevention services a covered category under section 1905 and requires states to include those services in benchmark or alternative benefit plans.
It also prohibits applying Medicaid cost‑sharing rules to these services and extends equivalent no‑cost coverage for CHIP enrollees and for pregnancy‑related assistance where a State provides it. States that need legislative changes get a transition window to conform their plans.Finally, federal employees get the same baseline: carriers in the Federal Employees Health Benefits Program must include the HIV prevention drugs and associated services and may not impose cost‑sharing.
Across programs the statutory text explicitly references the services and related counseling, lab testing, adherence support, and clinical follow‑up listed in current U.S. Public Health Service clinical practice guidelines, which anchors coverage content to the contemporaneous clinical standard.Operationally, plans and providers will need to update formularies, claims edits, prior‑authorization and utilization‑management rules, and billing/coding practices. Pharmacy benefit managers, plan sponsors, and state Medicaid offices will have to decide how to manage access while preserving budget controls, because the statute narrows one common tool (prior authorization) and leaves others—like formulary placement and therapeutic equivalence—available.
The Five Things You Need to Know
The bill adds a new item to PHSA section 2713(a) explicitly listing FDA‑approved HIV prevention drugs and associated services as preventive services that must be covered without patient cost‑sharing.
It creates a new PHSA section 2729A that generally prohibits preauthorization for the covered HIV prevention services, but allows preauthorization for a specific drug if a therapeutically equivalent drug is covered without preauthorization.
Medicare changes include adding an ‘‘HIV prevention services’’ definition to section 1861 and amending section 1833 to require 100% payment for those services (eliminating Part B coinsurance), and a separate statutory carve‑out removes Part D deductible and cost‑sharing for HIV prevention drugs.
Medicaid and CHIP are amended to make HIV prevention services a mandatory covered category under section 1905 and 2103, prohibit cost‑sharing for those services, and require inclusion in benchmark coverage rules; states that need legislative changes get a delayed compliance window.
FEHB carriers must cover HIV prevention drugs and the full suite of related services without any cost‑sharing, via an added paragraph to 5 U.S.C. 8904, effective for the first plan year beginning after enactment.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Adds HIV prevention to required preventive benefits and limits prior authorization
The bill amends PHSA section 2713(a) by adding an explicit preventive‑services item that names FDA‑approved HIV prevention drugs (PrEP and PEP), administrative fees, labs/diagnostics, counseling, adherence support, and guideline‑recommended follow‑up. It also inserts a new section 2729A that blocks preauthorization for those services except where a plan requires it for a particular drug but not for a therapeutically equivalent alternative. Practically, plans must remove member cost‑sharing and revoke prior‑auth edits tied to NDCs/CPT codes for covered items, while preserving formulary and therapeutic equivalence levers.
Defines HIV prevention services and eliminates Part B coinsurance/deductible for them
The bill adds a new subsection defining ‘‘HIV prevention services’’ in section 1861 and inserts that definition into the Part B benefit categories. It amends section 1833(a)(1) to require Medicare to pay 100 percent for those services (subject to fee‑schedule and outpatient payment rules), and changes section 1833(b) so the Part B deductible does not apply for those drugs. Administratively, CMS will need to map codes and decide which items are OPD versus physician/clinic services for payment application.
Removes Part D deductible and cost‑sharing for HIV prevention drugs and adjusts LIS rules
Amendments to section 1860D–2 add a new paragraph eliminating the Part D deductible and any coinsurance or copay for covered drugs used to prevent HIV. The bill also updates the low‑income subsidy and beneficiary cost‑sharing cross‑references to reflect that no cost‑sharing applies. Plan formularies, benefit designs, and CMS Part D bidder pricing will all require adjustment to reflect zero‑member liability for these products.
Makes HIV prevention services a mandatory Medicaid benefit and bans cost‑sharing
The bill amends section 1905 to include HIV prevention services among mandatory covered categories and defines the term in a new subsection. It also prohibits states from imposing cost‑sharing for these services and requires inclusion in benchmark plan rules (section 1937). States that need enacting legislation get a delayed compliance window tied to their legislative calendar, which preserves state flexibility to enact implementing statutes but limits how long they can delay coverage.
Requires CHIP coverage of HIV prevention services and bans cost‑sharing
Section 2103 is amended to require that child health assistance include coverage of HIV prevention services for targeted low‑income children (and pregnancy‑related assistance when offered). The bill also amends CHIP cost‑sharing language to ensure these services are provided without beneficiary cost‑sharing in the program’s established coverage tracks.
Adds FEHB requirement to cover HIV prevention services with no cost‑sharing
The measure inserts language into 5 U.S.C. 8904 directing that FEHB plans must include benefits for FDA‑approved HIV prevention drugs and associated services and may not impose any cost‑sharing. Carriers participating in FEHB will need to update benefits and member materials and coordinate with military and VA programs where overlap occurs.
Staggered effective dates and a state transition for Medicaid/CHIP
Most private‑plan and FEHB provisions apply to the first plan year beginning after enactment; Part D and Medicaid/CHIP provisions follow the same plan‑year timing language. Medicare Part B payment and deductible changes take effect on January 1 of the first calendar year beginning after enactment. States that require legislative action get a delayed compliance window tied to their next legislative session.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People at substantial risk for HIV: Eliminating cost‑sharing and many prior‑auth obstacles reduces out‑of‑pocket prices and administrative barriers that have limited PrEP/PEP uptake.
- Medicare beneficiaries needing prevention: Part B and Part D liability reductions lower financial barriers for Medicare‑eligible adults at risk of HIV.
- Children and pregnant people covered by Medicaid/CHIP: States must include these services in benefit packages without cost‑sharing, increasing access for low‑income populations.
- Federal employees and their dependents: FEHB enrollees gain no‑cost access which aligns federal employees with other federally mandated coverage standards.
- Public health programs and clinicians: Greater uptake of PrEP/PEP can expand prevention work and may make clinic outreach and HIV‑prevention programs more efficient by reducing patient financial barriers.
Who Bears the Cost
- Private insurers and plan sponsors: Eliminating member cost‑sharing and restricting prior authorization shifts more utilization and direct drug costs to insurers, which may affect premiums and employer contributions.
- Medicare Trust funds and taxpayers: Part B and Part D payment changes increase federal program spending for prevention drugs, labs, and visits.
- State Medicaid programs: Mandatory coverage and cost‑sharing bans increase state Medicaid outlays and may require states to adjust budgets or apply for waivers or other offsets.
- Pharmacy benefit managers and formularies: PBMs lose a common utilization tool (prior authorization) for these drugs and may face margin pressure or operational changes to manage access through formulary placement and rebate arrangements.
- Clinics and providers: Providers must absorb administrative changes—new coding, intake processes, adherence counseling delivery, and potentially higher visit volumes without additional programmatic funding.
Key Issues
The Core Tension
The central dilemma is access versus allocation: the bill expands patient access by removing direct financial and many administrative barriers, but it does so by reallocating costs and managerial control to payers and public programs—potentially increasing premiums, program spending, or prompting payers to use less transparent controls (like formulary placement) that can recreate barriers in a different form.
The bill narrows one major utilization‑management lever—prior authorization—while leaving other levers (formulary placement, step therapy via therapeutic equivalence, and network design) intact. That creates a practical question: will payers respond by tightening formulary tiers or altering reimbursement to control utilization, which could reintroduce access frictions in different forms?
The statutory exception that allows preauthorization when a therapeutically equivalent drug is available without prior authorization invites disputes over equivalence determinations and could encourage manufacturers and PBMs to jockey over preferred status.
Implementation logistics are also unclear. The statute ties covered services to ‘‘current United States Public Health Service clinical practice guidelines,’’ which provides clinical specificity but requires plans and providers to track guideline changes and build those updates into coverage and claims logic.
Payment language—particularly the Part B requirement to pay 100 percent of the lesser of actual charge or the applicable fee schedule—may generate billing disputes, seams between facility/OPD payment rules, and questions about whether ‘‘without limitation’’ for related services permits broad billing for ancillary care. For Medicaid, the state legislative compliance window reduces immediate disruption but could produce uneven access across states during the transition period.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.